Compare ABEO & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | JRVR |
|---|---|---|
| Founded | 1974 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.5M | 209.9M |
| IPO Year | 2005 | 2014 |
| Metric | ABEO | JRVR |
|---|---|---|
| Price | $2.42 | $2.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $15.56 | $3.73 |
| AVG Volume (30 Days) | ★ 2.2M | 386.4K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 1.37% |
| EPS Growth | ★ 165.16 | 125.82 |
| EPS | ★ N/A | N/A |
| Revenue | $2,998,000.00 | ★ $687,614,000.00 |
| Revenue This Year | $675.42 | N/A |
| Revenue Next Year | $126.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $2.09 | $2.90 |
| 52 Week High | $7.65 | $7.20 |
| Indicator | ABEO | JRVR |
|---|---|---|
| Relative Strength Index (RSI) | 27.49 | 25.14 |
| Support Level | $2.09 | N/A |
| Resistance Level | $5.77 | $4.16 |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 15.88 | 1.69 |
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.